Epidermolysis bullosa
MONDO:0006541Epidermolysis bullosa (EB) is a group of genetic skin diseases that cause the skin to blister very easily. Blisters form in response to minor injuries or friction, such as rubbing or scratching. There are four main types of epidermolysis bullosa: dystrophic epidermolysis bullosa Epidermolysis bullosa simplex Junctional epidermolysis bullosa Kindler Syndrome Identifying the exact type can be hard because there are many subtypes of EB. Within each type or subtype, a person may be mildly or severely affected. The disease can range from being a minor inconvenience to completely disabling, and fatal in some cases. Most types of EB are inherited. The inheritance pattern may be autosomal dominant or autosomal recessive. Management involves protecting the skin, reducing friction against the skin, and keeping the skin cool.
Also known as: epidermolysis bullosa, EB
44 clinical trials for this condition and its sub-types, 23 tagged with Epidermolysis bullosa itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Epidermolysis bullosa
-
Inherited epidermolysis bullosa 5 trials · 37 incl. sub-types
4 sub-types
- Epidermolysis bullosa dystrophica 23 trials · 30 incl. sub-types Sub-types →
- Junctional epidermolysis bullosa 6 trials · 8 incl. sub-types Sub-types →
- Epidermolysis bullosa simplex 5 trials Sub-types →
- Kindler syndrome 0 trials Sub-types →
-
Acquired epidermolysis bullosa 3 trials
Most studied deeper sub-types
-
New cream could help kids with 'Butterfly Skin' heal faster
Disease control Recruiting nowThis phase 3 trial tests whether a cream called SD-101 can help close wounds in children with epidermolysis bullosa (EB), a condition that causes fragile, blistering skin. About 80 children aged 1 month to 12 years will apply the cream or a placebo to their whole body for 2 month…
Phase 3 • Sponsor: Paradigm Therapeutics • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New gel could ease blistering for skin disorder patients
Disease control Recruiting nowThis study tests a gel called TolaSure on people aged 4 and older with epidermolysis bullosa simplex, a condition that causes fragile skin and blisters. For the first 2 months, some participants get the gel and others get a placebo; then everyone gets the gel for another 2 months…
Phase 2 • Sponsor: BioMendics, LLC • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New combo therapy aims to heal wounds in rare skin disease
Disease control Recruiting nowThis study tests whether adding IV IgG treatment to standard VYJUVEK therapy can help wounds heal faster and reduce blistering in people with recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic skin condition. Eight participants will receive IV IgG alongside their u…
Phase 1/2 • Sponsor: M. Peter Marinkovich • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Lab-Grown skin patch could heal wounds in 'Butterfly Children'
Disease control Recruiting nowThis study tests a new skin graft made from a patient's own cells, genetically modified to produce a missing protein. It aims to safely heal wounds in 9 people with recessive dystrophic epidermolysis bullosa (RDEB), a rare disease that causes fragile, blistering skin. The graft i…
Phase 1/2 • Sponsor: CHU de Quebec-Universite Laval • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New gel could help heal wounds in rare skin disease
Disease control Recruiting nowThis study tests a gel called Oleogel-S10 on skin wounds in people with inherited epidermolysis bullosa (EB), a condition that causes fragile, blistering skin. The trial includes 6 Japanese children and adults with junctional or dystrophic EB. Participants apply the gel to wounds…
Phase 3 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New gel could ease pain and heal wounds for kids with butterfly skin
Symptom relief Recruiting nowThis study tests a gel called TCP-25 on people with epidermolysis bullosa (EB), a condition that causes fragile skin and painful blisters. About 32 people aged 4 and older with certain types of EB will have two matching wounds treated—one with the study gel and one with a placebo…
Phase 2 • Sponsor: Xinnate AB • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
New eye drop battle: which offers better dry eye relief?
Symptom relief Recruiting nowThis study compares two preservative-free eye drops, Artelac Complete MDO and VISMED MULTI, for treating moderate to severe dry eye disease. About 160 adults who have used tear substitutes for at least a month will use one of the two drops for 90 days. Researchers will measure ch…
Sponsor: Dr. Gerhard Mann chem.-pharm. Fabrik GmbH • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
Can an existing drug calm the itch of rare genetic skin diseases?
Symptom relief Recruiting nowThis early-phase study is testing whether dupilumab, a drug already used for eczema, can reduce severe itching in people with various genetic skin disorders. The trial will enroll 30 participants and last 26 months, including a 16-week treatment period and a longer extension phas…
Early phase 1 • Sponsor: Northwestern University • Aim: Symptom relief
Last updated Jun 27, 2026 12:28 UTC
-
Could lying flat vs. on your side change esophageal test results?
Knowledge-focused Recruiting nowThis study tests whether the position a child lies in during an EndoFLIP procedure—flat on their back (supine) or on their left side—changes the measurements of esophageal function. EndoFLIP is an FDA-approved device that measures how well the esophagus opens and moves food. The …
Sponsor: Johns Hopkins University • Aim: Knowledge-focused
Last updated Aug 26, 2026 00:00 UTC